NASDAQ:EWTX Edgewise Therapeutics (EWTX) Stock Price, News & Analysis $18.98 +0.25 (+1.33%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$18.73▼$20.2450-Day Range$16.18▼$22.8752-Week Range$5.12▼$23.50Volume997,783 shsAverage Volume868,619 shsMarket Capitalization$1.77 billionP/E RatioN/ADividend YieldN/APrice Target$33.20 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Edgewise Therapeutics alerts: Email Address Edgewise Therapeutics MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside74.9% Upside$33.20 Price TargetShort InterestBearish14.47% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.62Based on 4 Articles This WeekInsider TradingSelling Shares$239,495 Sold Last QuarterProj. Earnings GrowthDecreasingFrom ($1.59) to ($1.98) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.47 out of 5 starsMedical Sector697th out of 936 stocksPharmaceutical Preparations Industry325th out of 436 stocks 3.5 Analyst's Opinion Consensus RatingEdgewise Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageEdgewise Therapeutics has only been the subject of 4 research reports in the past 90 days.Read more about Edgewise Therapeutics' stock forecast and price target. Previous Next 0.0 Short Interest Percentage of Shares Shorted14.47% of the float of Edgewise Therapeutics has been sold short.Short Interest Ratio / Days to CoverEdgewise Therapeutics has a short interest ratio ("days to cover") of 11.2, which indicates bearish sentiment.Change versus previous monthShort interest in Edgewise Therapeutics has recently increased by 1.18%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldEdgewise Therapeutics does not currently pay a dividend.Dividend GrowthEdgewise Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for EWTX. Previous Next 3.1 News and Social Media Coverage News SentimentEdgewise Therapeutics has a news sentiment score of 0.62. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Edgewise Therapeutics this week, compared to 2 articles on an average week.Search Interest4 people have searched for EWTX on MarketBeat in the last 30 days. MarketBeat Follows8 people have added Edgewise Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 700% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Edgewise Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $239,495.00 in company stock.Percentage Held by Insiders24.11% of the stock of Edgewise Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Read more about Edgewise Therapeutics' insider trading history. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Edgewise Therapeutics are expected to decrease in the coming year, from ($1.59) to ($1.98) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Edgewise Therapeutics is -12.25, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Edgewise Therapeutics is -12.25, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioEdgewise Therapeutics has a P/B Ratio of 4.19. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Edgewise Therapeutics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad DTIHeard about the 72-Hour Profit Surge? Read this…One of the most overlooked opportunities in the stock market is the 72-Hour Profit Surge... A short period of time where we can bet on a stock that is ALREADY “winning.” Let me give you a perfect example of how the Surge worked with Ross Stores. Back on November 16th, a little move was made that sent their stock soaring… The next day, my system would have alerted me that Ross Stores had entered the 72-Hour Profit Surge…Click here now to get all the details. About Edgewise Therapeutics Stock (NASDAQ:EWTX)Edgewise Therapeutics, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders. Its lead product candidate, EDG-5506, an orally administered small molecule that is in Phase II clinical trials, designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy. The company develops EDG-7500, a small molecule for the treatment of hypertrophic cardiomyopathy and other severe cardiac disorders that is in Phase I clinical trials. In addition, it develops a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address genetically defined muscle disorders. Edgewise Therapeutics, Inc. was incorporated in 2017 and is headquartered in Boulder, Colorado.Read More EWTX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart EWTX Stock News HeadlinesJuly 25 at 5:50 PM | markets.businessinsider.comRBC Capital Keeps Their Buy Rating on Edgewise Therapeutics (EWTX)July 17, 2024 | americanbankingnews.comEdgewise Therapeutics (NASDAQ:EWTX) Hits New 52-Week High at $23.50July 26, 2024 | Weiss Ratings (Ad)Nvidia’s Quiet $1 Trillion PivotNvidia recently added $277 billion in market cap … IN ONE DAY.May 14, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Sutro Biopharma (STRO), Edgewise Therapeutics (EWTX) and Forte Biosciences (FBRX)May 10, 2024 | finance.yahoo.comEdgewise Therapeutics Inc (EWTX) Reports First Quarter 2024 Financial ResultsMay 10, 2024 | businesswire.comEdgewise Therapeutics to Present at the RBC Capital Markets Global Healthcare Conference on May 15, 2024May 9, 2024 | investorplace.comEWTX Stock Earnings: Edgewise Therapeutics Beats EPS for Q1 2024May 6, 2024 | businesswire.comEdgewise Therapeutics Doses First Patient in Phase 2 CIRRUS-HCM Trial of EDG-7500 in Obstructive Hypertrophic Cardiomyopathy (HCM)July 26, 2024 | MarketBeat (Ad)We just added a $300 account credit to your MarketBeat subscriptionMarketBeat All Access is our complete suite of portfolio monitoring software, research tools, stock screeners, proprietary reports, and more. Upgrade today and get $300 off your 2024-2025 subscription. Free for 30 days.April 23, 2024 | businesswire.comEdgewise Receives European Medicines Agency (EMA) Orphan Drug Designations for Sevasemten (EDG-5506) for the Treatment of Becker and Duchenne Muscular DystrophiesApril 22, 2024 | seekingalpha.comJANX Janux Therapeutics, Inc.April 17, 2024 | investing.comEdgewise reports positive Becker trial results, plans discussionApril 17, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Edgewise Therapeutics (EWTX) and Progyny (PGNY)April 15, 2024 | businesswire.comEdgewise Therapeutics Announces Positive Two-Year Topline Results from the ARCH Open Label Trial of Sevasemten (EDG-5506) in Adults with Becker Muscular Dystrophy (Becker)March 28, 2024 | businesswire.comEdgewise Therapeutics Announces Upcoming Podium Presentation at the American College of Cardiology's 2024 Annual Scientific SessionMarch 27, 2024 | businesswire.comEdgewise Therapeutics to Present at the Cantor Virtual Muscular Dystrophy Symposium on April 2, 2024March 5, 2024 | finance.yahoo.comEdgewise Therapeutics to Present at the Leerink Partners Global Biopharma Conference on March 11, 2024February 28, 2024 | businesswire.comEdgewise Therapeutics to Present on EDG-5506 for the Treatment of Becker Muscular Dystrophy at the 2024 MDA Clinical and Scientific ConferenceSee More Headlines Receive EWTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Edgewise Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/09/2024Today7/26/2024Next Earnings (Estimated)8/08/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:EWTX CUSIPN/A CIK1710072 Webwww.edgewisetx.com Phone720-262-7002FaxN/AEmployees60Year FoundedN/APrice Target and Rating Average Stock Price Target$33.20 High Stock Price Target$48.00 Low Stock Price Target$25.00 Potential Upside/Downside+74.6%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)($1.55) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-100,160,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-29.09% Return on Assets-27.57% Debt Debt-to-Equity RatioN/A Current Ratio37.08 Quick Ratio37.08 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$4.53 per share Price / Book4.20Miscellaneous Outstanding Shares93,400,000Free Float70,881,000Market Cap$1.78 billion OptionableOptionable Beta0.14 Ten Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free Report Key ExecutivesDr. Peter A. Thompson FACP (Age 64)M.D., Co-Founder & Independent Chairman Comp: $76kDr. Kevin Koch Ph.D. (Age 64)President, CEO & Director Comp: $905.52kDr. Badreddin Edris Ph.D. (Age 37)Co-Founder & Independent Director Comp: $43kDr. Behrad Derakhshan Ph.D. (Age 44)Chief Business Officer Comp: $630.67kDr. Joanne M. Donovan M.D. (Age 67)Ph.D., Chief Medical Officer Comp: $696.4kDr. Alan J. Russell Ph.D. (Age 54)Co-Founder, Chief Scientific Officer & Director Comp: $657.52kMr. R. Michael Carruthers (Age 66)Chief Financial Officer Comp: $386.01kMr. John R. Moore (Age 60)General Counsel Dr. Marc Semigran M.D. (Age 67)Chief Development Officer More ExecutivesKey CompetitorsKura OncologyNASDAQ:KURAZogenixNASDAQ:ZGNXPTC TherapeuticsNASDAQ:PTCTIntersect ENTNASDAQ:XENTAnaptysBioNASDAQ:ANABView All CompetitorsInsiders & InstitutionsBank of New York Mellon CorpBought 56,447 shares on 7/26/2024Ownership: 0.288%SG Americas Securities LLCBought 55,706 shares on 7/12/2024Ownership: 0.069%Simplicity Wealth LLCBought 15,218 shares on 7/10/2024Ownership: 0.016%Opaleye Management Inc.Sold 34,000 shares on 5/29/2024Ownership: 0.712%Artal Group S.A.Bought 811,718 shares on 5/17/2024Ownership: 0.869%View All Insider TransactionsView All Institutional Transactions EWTX Stock Analysis - Frequently Asked Questions How have EWTX shares performed this year? Edgewise Therapeutics' stock was trading at $10.94 at the beginning of the year. Since then, EWTX shares have increased by 73.5% and is now trading at $18.98. View the best growth stocks for 2024 here. How were Edgewise Therapeutics' earnings last quarter? Edgewise Therapeutics, Inc. (NASDAQ:EWTX) issued its quarterly earnings results on Thursday, May, 9th. The company reported ($0.33) earnings per share for the quarter, topping analysts' consensus estimates of ($0.39) by $0.06. When did Edgewise Therapeutics IPO? Edgewise Therapeutics (EWTX) raised $150 million in an IPO on Friday, March 26th 2021. The company issued 10,000,000 shares at a price of $14.00-$16.00 per share. J.P. Morgan, Goldman Sachs, SVB Leerink and Wedbush PacGrow served as the underwriters for the IPO. Who are Edgewise Therapeutics' major shareholders? Edgewise Therapeutics' top institutional investors include Bank of New York Mellon Corp (0.29%), SG Americas Securities LLC (0.07%) and Simplicity Wealth LLC (0.02%). Insiders that own company stock include Peter A Thompson, Orbimed Advisors Llc, Holdings A/S Novo, R Michael Carruthers, Joanne M Donovan, Kevin Koch, Behrad Derakhshan, Alan J Russell and John R Moore. View institutional ownership trends. How do I buy shares of Edgewise Therapeutics? Shares of EWTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:EWTX) was last updated on 7/26/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredThis student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... ...Monument Traders Alliance | SponsoredCollapse of the PetrodollarThe death of the "petrodollar" seems imminent. And the implications could not be worse for Americans. Ru...Colonial Metals | SponsoredRare signal predicts 50% market drop - before electionThe market is near all-time highs, we're told that unemployment is low, AI's a gift to humanity, and the FED w...Behind the Markets | SponsoredMust-See: Elon’s New Invention is Absolutely InsaneCould Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | SponsoredElon to Transform U.S. Economy? A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” ...Porter & Company | Sponsored5 Stocks that could triple in a week Robinhood traders have piled $78 billion into this market... Driving tiny tech stock gains of 3,000%, 8,942...Traders Agency | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Edgewise Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Edgewise Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free EWTX Stock Alerts